Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Landiolol versus standard of care in septic shock with hypercontractility
2024-518251-31-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in septic shock comparing Landiolol with Standard of care (2 arms). Primary endpoint: 28-day mortality. Planned start Oct 2024; status: authorised.
02
Drugs
landiolol
03
Conditions
septic shock
Beyond the preview
Go deeper on 2024-518251-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518251-31-00.